Member Info for Brand

Cheers!

Cheers Wigster - just had a look on the clinical trials record and it still looks to say 'not yet recuiting'

https://clinicaltrials.gov/ct2/show/NCT05605093

Have you found an alternative listing of the trial showing differently? Not looking to dispute just keen to see where it's mentioned.

Hmmm, now I wonder why two of the most obnoxious posters on this BB would have it in for someone who has shared an immense amount of relevant and insightful info re SNG001 and the company. Hmmmmmmm.

https://www.ft.com/content/325b75d9-5148-4635-b9c2-63244fa74936

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/325b75d9-5148-4635-b9c2-63244fa74936

Only 66 healthcare deals have been announced in the first couple of weeks of 2023, compared with 247 during the same period last year — the worst record in 20 years, according to Refinitiv data. Overall deal value is down 27 per cent to $4.9bn.

In pharma and biotech, there have been 22 deals announced so far this year, compared with 70 over the same period last year, though the overall value rose from $2.6bn to $4.4bn

immunostimulants, such as interferon and Mycobacterium vaccae, was the smallest and the evidence was the most fragile compared with immunosuppressants including nonspecific (hydroxychloroquine, glucocorticoid, colchicine) or specific ones (tofacitinib, bocilizumab). This could be explained by the immune features of the cytokine storm; in the early stage of the infection the secretion of interferon was delayed, whereas in the late stage, pro-inflammatory cytokines were excessively secreted [33]. Immunostimulants could be urgently needed in the early stage and immunosuppressants could work better in the late stage [34]. However, the RCTs that adopted immunostimulants were performed in the hospitalized patients, even some of them were severe cases at late stage [35,36,37,38,39]. The higher FI of specific immunosuppressants supported the judgment that new generation cytokine-targeted therapies, such as tofacitinib and tocilizumab, could be the most promising drugs [34].

Conclusion
The robustness of significant dichotomous outcomes of COVID-19 treatments was fragile and affected by the outcomes of interest, patients, interventions, P value, and absolute difference of events between the groups. FI was an useful quantitative metric for the binary significant outcomes on COVID-19 treatments.
https://link.springer.com/article/10.1007/s44231-022-00027-y

5 approved treatments and 1 unapproved included - really interesting thanks for sharing Titiania.

Back to the question at hand. I'm sure others would be better placed to answer this, but aren't steroids only meant to be used for inpatient - after a certain point in disease progression?

It does beg the question what soc would be in the shionogi arm of strive too

So why hire a clinical trials assistant?

"why would you pay £200M for a company with a MCAP of £15M ?"

The first answer is because someone else is willing to pay £199m

The second answer is, because you can make much more

A very interesting read - published 1st Jan 23

https://www.sciencedirect.com/science/article/pii/S2405803322001947

"Treatment of various cancers with IFN-I as a single agent has had only very limited success. Recent research suggests that IFN-I can facilitate cell killing in combination with DNA-damaging agents, including irradiation and chemotherapy. Furthermore, blocking of chronic IFN-I synthesis and responses can sensitize cancer cells to DNA damage, since chronic IFN-I promotes resistance to DNA damage."

Going back to the panel w rick bright, alot of the talk was re outpatient use and 'an anti-viral penicillin' - pure guess work but JV and company sponsored trial for inpatient, Platform trial for outpatient?

I recall the argument that the universal trial was in effect 'sizing the market'for sng001 and still think this as good an explanation as any but if it was that straight forward you would have expected more reaction from the market. J&J don't have a dog in the COVID fight so it would seem a good fit as well.

Interesting little tidbit w Universal - this page surfaced a few weeks back, nothing revelatory in there, but the first doc is dated 8th Apr, which is about 6 weeks after sprinter TLR and wasn't announced until September.

https://www.southampton.ac.uk/ctu/trialportfolio/listoftrials/universal.page#essential_trial_documentation

Not outright disagreeing, but why would Jansen pay for data that would design a govt lead trial for sng?

It and the twitter post are both very 'casual' - we know however that multiple folks were contacting the company asking if they were attending, so it may be more aimed at that then anyone else attending the conference.

Did you mean the peer reviewed long Covid data?

https://academic.oup.com/ofid/article/9/Supplement_2/ofac492.1879/6903622?login=false

Results
When compared to placebo, SNG001 reduced the relative risk of common symptoms of long COVID (fatigue/malaise [RRR=35.4%]; dyspnoea [RRR=28.3%]; loss of smell and/or taste [RRR=61.4%]). Analysis of the PROs is ongoing.

Personally I think our Leeds Era is still to come.

https://www.google.com/amp/s/m.koreaherald.com/amp/view.php%3fud=20220929000831

Great city Leeds, absolutely feral fans - which I guess matches this BB tbf

Someone quite clever pointed out there was a NY message from RM on the same date last year and the next day we had the rns announcing the partnership with Ashfield Engage.

So prob best to not over analyse it and accept it's business as usual.

Clutching at straws here lads. Try a new narrative

Must be a big trial.